Biogen (BIIB) expects Q4 results to included a research milestone of USD 222mln; will impact adj. EPS by 1.26/shr

Biogen's announcement of a Q4 research milestone worth USD 222 million, which will add USD 1.26 to adjusted EPS, is positive for investor sentiment as it highlights progress in their pipeline.

Newsquawk StaffPublished On the live feed at 7 more headlines followed before this page went public
Newsquawk headlinesUTC

Chiina will strengthen cost investigations and price monitoring for NEV, according to reports

An Egyptian source says Palestinian factions are meeting in Cairo to discuss power transfer in Gaza to technocrats; no American or Israeli objections

Biogen (BIIB) expects Q4 results to included a research milestone of USD 222mln; will impact adj. EPS by 1.26/shr

SLB (SLB) is poised to reap gains from Trump’s plan to leverage Venezuelan oil, is in position to win some of the first contracts under plan to revive Venezuela’s ailing oil industry, FT reports

Sandoz (SDZ) confirms approval of Ondibta by the EU Commission; strengthening their overall Biosimilars leadership and position in diabetes

Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.

Free. No signup, no card.
Context

This could strengthen the stock's position within the biotechnology sector and potentially lead to upward adjustments in future earnings estimates. Keep an eye on sector peers and general market reaction, as this may influence trading dynamics in related equities and healthcare indices.

Related headlines

The whole workspace, free to try.

Try it free